| Interactive effects of molecular, therapeutic, and patient factors on outcome of diffuse low-grade glioma SL Hervey-Jumper, Y Zhang, JJ Phillips, RA Morshed, JS Young, ... Journal of Clinical Oncology 41 (11), 2029-2042, 2023 | 88 | 2023 |
| Interactions of age and blood immune factors and noninvasive prediction of glioma survival AM Molinaro, JK Wiencke, G Warrier, DC Koestler, P Chunduru, JY Lee, ... JNCI: Journal of the National Cancer Institute 114 (3), 446-457, 2022 | 15 | 2022 |
| DNA methylation as a pharmacodynamic marker of glucocorticoid response and glioma survival JK Wiencke, AM Molinaro, G Warrier, T Rice, J Clarke, JW Taylor, ... Nature communications 13 (1), 5505, 2022 | 12 | 2022 |
| “De novo replication repair deficient glioblastoma, IDH-wildtype” is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade S Hadad, R Gupta, NA Oberheim Bush, JW Taylor, JE Villanueva-Meyer, ... Acta Neuropathologica 147 (1), 3, 2024 | 10 | 2024 |
| Pre-surgery immune profiles of adult glioma patients PM Bracci, T Rice, HM Hansen, SS Francis, S Lee, LS McCoy, ... Journal of Neuro-oncology 159 (1), 103-115, 2022 | 9 | 2022 |
| Comparative analysis of the DNA methylation landscape in CD4, CD8, and B memory lineages Z Zhang, R Butler, DC Koestler, S Bell-Glenn, G Warrier, AM Molinaro, ... Clinical Epigenetics 14 (1), 173, 2022 | 8 | 2022 |
| The relationship between stimulation current and functional site localization during brain mapping RH Muster, JS Young, PYM Woo, RA Morshed, G Warrier, S Kakaizada, ... Neurosurgery 88 (6), 1043-1050, 2021 | 7 | 2021 |
| Enrichment of a neutrophil-like monocyte transcriptional state in glioblastoma myeloid suppressor cells JK Wiencke, E Nissen, DC Koestler, SJ Tamaki, CM Tamaki, HM Hansen, ... Research Square, 2023 | 2 | 2023 |
| Evaluation of cross-platform compatibility of a DNA methylation-based glucocorticoid response biomarker E Tang, JK Wiencke, G Warrier, H Hansen, L McCoy, T Rice, PM Bracci, ... Clinical epigenetics 14 (1), 136, 2022 | 2 | 2022 |
| BIOM-43. CROSS-PLATFORM ROBUSTNESS IN THE GLUCOCORTICOID RESPONSE PHARMACODYNAMIC BIOMARKER E Tang, J Wiencke, G Warrier, H Hansen, L McCoy, T Rice, P Bracci, ... Neuro-oncology 23 (Suppl 6), 2021 | 1 | 2021 |
| DISP-05. SUPERVISED MACHINE LEARNING PREDICTION OF THERAPEUTIC CLINICAL TRIAL ENROLLMENT FOR MINORITY PATIENTS AND WOMEN IN NEURO-ONCOLOGY M Mehari, G Warrier, A Dada, A Kabir, A Haskell-Mendoza, S Reihl, ... Neuro-Oncology 26 (Supplement_8), viii147-viii147, 2024 | | 2024 |
| Predicting therapeutic clinical trial enrollment for underrepresented patients in neuro-oncology using supervised machine learning. M Mehari, G Warrier, A Dada, A Kabir, UN Chukwueke, AB Porter, ... Journal of Clinical Oncology 42 (16_suppl), 1614-1614, 2024 | | 2024 |
| Revitalizing the accrual of women and minorities: Unique drivers of therapeutic clinical trial enrollment for underrepresented patients with diffuse glioma M Mehari, G Warrier, S Reihl, A Dada, A Kabir, M Negussie, CN Gonzales, ... Cancer Research 84 (6_Supplement), 1006-1006, 2024 | | 2024 |
| Oligodendroglioma patient survival is associated with circulating B-cells and age JW Taylor, G Warrier, HM Hansen, L McCoy, T Rice, G Guerra, SS Francis, ... Neuro-Oncology Advances 6 (1), vdae143, 2024 | | 2024 |
| EPID-12. SURVIVAL IS ASSOCIATED WITH CIRCULATING B-CELLS AND AGE AMONG OLIGODENDROGLIOMA PATIENTS J Taylor, G Warrier, H Hansen, L McCoy, T Rice, G Guerra, S Francis, ... Neuro-Oncology 25 (Suppl 5), v117, 2023 | | 2023 |
| BIOM-42. LONGITUDINAL IMMUNE PROFILES OF LOWER GRADE ADULT GLIOMA PATIENTS G Guerra, S Francis, A Molinaro, J Taylor, G Warrier, P Bracci, T Rice, ... Neuro-Oncology 25 (Suppl 5), v13, 2023 | | 2023 |
| OS13. 6. A SURVIVAL IS ASSOCIATED WITH CIRCULATING B-CELLS AND AGE AMONG OLIGODENDROGLIOMA PATIENTS JW Taylor, G Warrier, H Hansen, L McCoy, T Rice, G Guerra, S Francis, ... Neuro-Oncology 25 (Suppl 2), ii25, 2023 | | 2023 |
| SURG-15. A NOVEL RISK MODEL TO DEFINE THE RELATIVE BENEFIT OF MAXIMAL EXTENT OF RESECTION WITHIN PROGNOSTIC GROUPS IN NEWLY DIAGNOSED DIFFUSE LOW-GRADE GLIOMA S Hervey-Jumper, A Molinaro, J Phillips, R Morshed, J Young, Y Zhang, ... Neuro-oncology 22 (Supplement_2), ii206-ii206, 2020 | | 2020 |
| SURG-18. THE IMPACT OF NEUROLOGIC IMPAIRMENTS ON THE RELATIVE BENEFIT OF MAXIMAL EXTENT OF RESECTION IN NEWLY DIAGNOSED IDH-WILD TYPE GLIOBLASTOMA S Hervey-Jumper, A Molinaro, CD Ore, D Brown, Y Zhang, R Morshed, ... Neuro-oncology 22 (Supplement_2), ii207-ii207, 2020 | | 2020 |
| EPCO-25. AN IMMUNOMETHYLOMIC PLATFORM INTEGRATING SYSTEMIC IMMUNE PROFILES AND EPIGENETIC AGE IN NEURO-ONCOLOGY A Molinaro, J Wiencke, G Warrier, JY Lee, D Koestler, H Hansen, T Rice, ... Neuro-oncology 22 (Supplement_2), ii74-ii74, 2020 | | 2020 |
